Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (NVO)
NYSE:NVO
NVO Analyst Ratings
Moderate Buy
5 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NVO Stock 12 Month Forecast
Average Price Target
$110.36
▲(53.85% Upside)
| Highest Price Target$159.50 | Average Price Target$110.36 | Lowest Price Target$90.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
BMO Capital
Reiterated
03/24/25
Berenberg Bank
Reiterated
03/24/25
Morgan Stanley
Reiterated
03/10/25
Stifel Nicolaus
Downgraded
03/03/25
Bank of America Securities
Reiterated
02/25/25
TD Cowen
Reiterated
02/24/25
CFRA
Reiterated
01/21/25
Argus Research
Reiterated
01/16/25
Goldman Sachs
Reiterated
01/13/25
Jefferies
$81.5
Sell
13.62%
Upside
Reiterated
12/20/24
Jefferies sees Novo dropping 'at least' 10%-15% on obesity data Jefferies sees Novo dropping 'at least' 10%-15% on obesity data
Erste Group
―
Hold
―
Downgraded
10/28/24
Novo Nordisk downgraded to Hold from Buy at Erste GroupNovo Nordisk downgraded to Hold from Buy at Erste Group
Citi
―
Buy
―
Reiterated
08/08/24
Novo Nordisk should be bought on earnings pullback, says CitiNovo Nordisk should be bought on earnings pullback, says Citi
J.P. Morgan
―
Buy
―
Reiterated
07/11/24
Novo Nordisk complete response letter 'minor negative,' says JPMorganNovo Nordisk complete response letter 'minor negative,' says JPMorgan
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
BMO Capital
Reiterated
03/24/25
Berenberg Bank
Reiterated
03/24/25
Morgan Stanley
Reiterated
03/10/25
Stifel Nicolaus
Downgraded
03/03/25
Bank of America Securities
Reiterated
02/25/25
TD Cowen
Reiterated
02/24/25
CFRA
Reiterated
01/21/25
Argus Research
Reiterated
01/16/25
Goldman Sachs
Reiterated
01/13/25
Jefferies
$81.5
Sell
13.62%
Upside
Reiterated
12/20/24
Jefferies sees Novo dropping 'at least' 10%-15% on obesity data Jefferies sees Novo dropping 'at least' 10%-15% on obesity data
Erste Group
―
Hold
―
Downgraded
10/28/24
Novo Nordisk downgraded to Hold from Buy at Erste GroupNovo Nordisk downgraded to Hold from Buy at Erste Group
Citi
―
Buy
―
Reiterated
08/08/24
Novo Nordisk should be bought on earnings pullback, says CitiNovo Nordisk should be bought on earnings pullback, says Citi
J.P. Morgan
―
Buy
―
Reiterated
07/11/24
Novo Nordisk complete response letter 'minor negative,' says JPMorganNovo Nordisk complete response letter 'minor negative,' says JPMorgan
NVO Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
2
2
2
1
1
Buy
13
10
13
11
11
Hold
2
2
5
5
7
Sell
0
1
1
1
0
Strong Sell
0
0
0
0
0
total
17
15
21
18
19
Each month's total comprises the sum of three months' worth of ratings.
NVO Financial Forecast
NVO Stock Forecast FAQ
What is NVO’s average 12-month price target, according to analysts?
Based on analyst ratings, Novo Nordisk’s 12-month average price target is $110.36.
What is NVO’s upside potential, based on the analysts’ average price target?
Novo Nordisk has 53.85% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NVO a Buy, Sell or Hold?
Novo Nordisk has a consensus rating of Moderate Buy which is based on 5 buy ratings, 5 hold ratings and 0 sell ratings.
What is Novo Nordisk’s price target?
The average price target for Novo Nordisk is $110.36. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $159.50 ,the lowest forecast is $90.00. The average price target represents 53.85% Increase from the current price of $71.73.
The highest analyst price target is $159.50 ,the lowest forecast is $90.00. The average price target represents 53.85% Increase from the current price of $71.73.
What do analysts say about Novo Nordisk?
Novo Nordisk’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of NVO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.